Our small molecule selective antagonists of the PGF2α pathway have been comprehensively characterized using the standard battery of pharmacological tools, as well disease relevant studies specific to the PGF2α pathway. Their superior profiles include:
- High potency in inhibiting PGF2α pathway in rodents and humans, at sub-nanomolar range,
- Over 100x selectivity for the PGF2α pathway over other prostaglandin pathways,
- Excellent pharmacokinetics (PK) profile amenable for oral administration,
- Clean safety profile based on extensive in vitro assessments,
- Preclinical efficacy and differentiation potential demonstrated in in vitro, ex vivo (human), and in vivo (animal) models.